Carbocysteine
Carbocysteine is a mucolytic agent and is used to reduce the viscosity of sputum.
Primary Characteristics
It is of Natural origin and belongs to L-Cysteine.
It belongs to Mucolytic Agents pharmacological group on the basis of mechanism of action and also classified in Mucolytic Agents pharmacological group. It is also classified under Respiratory Combination Products .
Molecular Weight: 179.2 · Solubility in Water: insoluble · Solubility in Alcohol: insoluble · Non-proprietary name: Carbocysteine.
Pharmacokinetics
Absorption: Carbocysteine has an oral bioavailability is 75% (±5%).
Distribution: Carbocysteine has a volume of distribution is 60.4 litre.
Elimination: plasma half-life is 1.33 hr, renal excretion is >95%.
Advertisement
Indications
Carbocysteine is primarily indicated in conditions like Advanced or metastatic breast cancer, Glue ear, Respiratory tract disorders.
Contraindications
None recorded.
Dosage
Carbocysteine's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 750 – 750 mg | — | Every 8h | PO | Initially (or 2.25gm in daily divided doses.) |
| 250 – 250 mg | — | Every 8h | PO | (Maintenance dose) when a responce is obtained. (or 1.5gm in daily divided doses as condition improves) |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
None recorded.
Side Effects
Carbocysteine in overdosage may give rise to further complications which include Gi bleeding , Convulsions .
The signs and symptoms that are produced after acute overdosage of Carbocysteine are GI disturbances.
Carbocysteine is known to cause more or less tolerable side effects which are usually transient. These include Dizziness, Dyspnea, Headache, Myalgia, Nausea, Palpitation, Psychiatric disturbance, Skin rashesX, Urinary incontinence.
Warnings / Precautions
Available Brands
Click on a strength to view available brands.
Single Ingredient
Multi-Ingredient Combinations
Storage Conditions
Drug Classification
- 1.25.2.2 — Expectorants